Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh/ Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA.
Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Am J Gastroenterol. 2022 Apr 1;117(4):654-667. doi: 10.14309/ajg.0000000000001605.
To determine whether percutaneous tibial nerve stimulation (PTNS) is superior to sham stimulation for the treatment of fecal incontinence (FI) in women refractory to first-line treatments.
Women aged 18 years or older with ≥3 months of moderate-to-severe FI that persisted after a 4-week run-in phase were randomized 2:1 (PTNS:sham stimulation) to 12 weekly 30-minute sessions in this multicenter, single-masked, controlled superiority trial. The primary outcome was change from baseline FI severity measured by St. Mark score after 12 weeks of treatment (range 0-24; minimal important difference, 3-5 points). The secondary outcomes included electronic bowel diary events and quality of life. The groups were compared using an adjusted general linear mixed model.
Of 199 women who entered the run-in period, 166 (of 170 eligible) were randomized, (111 in PTNS group and 55 in sham group); the mean (SD) age was 63.6 (11.6) years; baseline St. Mark score was 17.4 (2.7); and recording was 6.6 (5.5) FI episodes per week. There was no difference in improvement from baseline in St. Mark scores in the PTNS group when compared with the sham group (-5.3 vs -3.9 points, adjusted difference [95% confidence interval] -1.3 [-2.8 to 0.2]). The groups did not differ in reduction in weekly FI episodes (-2.1 vs -1.9 episodes, adjusted difference [95% confidence interval] -0.26 [-1.85 to 1.33]). Condition-specific quality of life measures did not indicate a benefit of PTNS over sham stimulation. Serious adverse events occurred in 4% of each group.
Although symptom reduction after 12 weeks of PTNS met a threshold of clinical importance, it did not differ from sham stimulation. These data do not support the use of PTNS as conducted for the treatment of FI in women.
为了确定经皮胫神经刺激(PTNS)是否优于假刺激,用于治疗对一线治疗无反应的女性粪便失禁(FI)。
本多中心、单盲、对照优势试验纳入年龄在 18 岁或以上、有≥3 个月中度至重度 FI 的女性,这些女性在 4 周的预试验阶段后仍有持续性 FI。将她们以 2:1(PTNS:假刺激)的比例随机分配至 12 周每周 30 分钟的治疗。主要结局是治疗 12 周后 St. Mark 评分(范围 0-24;最小有意义差异为 3-5 分)的 FI 严重程度从基线的变化。次要结局包括电子排便日记事件和生活质量。采用调整后的一般线性混合模型比较两组。
在进入预试验阶段的 199 名女性中,有 166 名(170 名符合条件的女性中有 166 名)被随机分配(PTNS 组 111 名,假刺激组 55 名);平均(SD)年龄为 63.6(11.6)岁;基线 St. Mark 评分为 17.4(2.7);每周记录的 FI 发作次数为 6.6(5.5)次。与假刺激组相比,PTNS 组的 St. Mark 评分从基线的改善没有差异(-5.3 与-3.9 分,调整后的差异[95%置信区间]为-1.3[-2.8 至 0.2])。两组每周 FI 发作次数的减少也没有差异(-2.1 与-1.9 次,调整后的差异[95%置信区间]为-0.26[-1.85 至 1.33])。特定于病情的生活质量指标并未表明 PTNS 优于假刺激。每组各有 4%的患者发生严重不良事件。
尽管 PTNS 治疗 12 周后的症状缓解达到了临床重要性的阈值,但与假刺激无差异。这些数据不支持使用 PTNS 进行女性 FI 的治疗。